Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryCRO

PUBLISHER: Grand View Research | PRODUCT CODE: 1571747

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1571747

Pharmaceutical CRO Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Pre-clinical), By Molecule Type (Small Molecules, Large Molecules), By Services, By Therapeutic Areas, By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 140 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Pharmaceutical CRO Market Growth & Trends:

The global pharmaceutical CRO market size is expected to reach USD 62.99 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to show a lucrative CAGR of 7.32% over the forecast period due to rising outsourcing trends and increasing R&D expenditure.

Pharmaceutical CROs provide outsourcing services to various pharmaceutical companies on a contract basis. Increasing outsourcing among pharmaceutical companies, growing investments in the R&D of new drugs, expansions in the pharmaceutical industry, and CRO support in reducing operational and capital expenses are some of the major factors anticipated to propel market growth in the forecast period.

Besides, increasing demand for CRO is driven by rising requirements for improved drug development, product maintenance, and related services, which is expected to drive market growth in the coming years. In addition, the substantial presence of key market players and ongoing clinical trials globally are expected to drive market growth. For instance, according to the U.S. National Library of Medicine, about 83,230 clinical trial studies are currently active and recruiting globally, which is anticipated to contribute to market growth. Likewise, increasing drug development activities, strategic initiatives such as innovation & acquisitions, the growing presence of pharmaceutical companies, and a surge in demand for pharmaceutical CRO innovative services are key factors propelling the market growth.

Furthermore, growing technological innovations pertaining to developing novel pharmaceutical drugs and rising research and development for biologics are anticipated to influence the market positively. Currently, pharmaceutical companies are increasingly bolstering their capacities in CRO's newer, highly specific expertise and technologies for the innovation of various small & large molecules. In addition, most pharmaceutical CROs have an emerging demand for small molecule drug candidates' development as CRO supports early discovery and preclinical drug development studies. For instance, in March 2023, Crown Bioscience & JSR Life Sciences Company mentioned it's a new site in Singapore, which will support the company in expanding its capacity for biotech & pharma companies. The site will help companies that engage in preclinical & translational oncology drug discovery and development.

Pharmaceutical CRO Market Report Highlights:

  • The clinical segment dominated the market with a revenue share of 75.85% in 2023 due to changing drug development scenarios and the need for sophisticated capabilities to help pharmaceutical companies advance drug manufacturing. In addition, cost-effectiveness and the increasing number of CROs are some of the key factors positively affecting market growth.
  • The small molecules segment dominated the market in 2023 owing to the increasing potential of targeted therapies, rising demand for personalized medicine, and pharmaceutical companies' growing interest in small molecules. Besides, the expanding pipeline of small molecule drugs is anticipated to create opportunities for CROs to provide services.
  • Based on service, clinical monitoring held the largest market share of 20.15% in 2023, which is attributed to the increase in the adoption of monitoring of regulatory requirements and clinical trial management, which includes protocol development to data analysis, making it a suitable option for a wide range of clinical trials.
  • In terms of therapeutic areas, the oncology segment held the largest market share of 30.46% in 2023. The segment is driven by the growing incidence of cancer, the rising aging population, and the robust demand for pharmaceuticals, contributing to its prominence in this field.
  • Asia Pacific dominated the market globally with a revenue share of 45.60% in 2023. The region's high share is due to an increased number of actively functioning CROs, especially in China and Japan, among others.
Show more
Product Code: GVR-4-68040-470-0

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Type Segment
    • 1.2.2. Molecule Type Segment
    • 1.2.3. Services Segment
    • 1.2.4. Therapeutic Areas Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pharmaceutical CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Rate of Clinical Research to Boost Demand For Outsourcing Services
      • 3.2.1.2. Increasing Adoption of Advanced Technologies
      • 3.2.1.3. Increasing Mergers and Collaborations
      • 3.2.1.4. Increasing Demand for Outsourcing Services Across The Developing Economies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Risk Associated with Data Security
      • 3.2.2.2. Monitoring Issues and Lack of Standardization
  • 3.3. Pharmaceutical CRO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Pharmaceutical CRO Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Pharmaceutical CRO Market Type Movement Analysis
  • 4.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Drug Discovery
    • 4.4.1. Drug discovery market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Target Validation
      • 4.4.2.1. Target validation market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Lead Identification
      • 4.4.3.1. Lead identification market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Lead Optimization
      • 4.4.4.1. Lead optimization market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Pre-Clinical
    • 4.5.1. Pre-Clinical market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Clinical
    • 4.6.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.2. Phase I Trial Services
      • 4.6.2.1. Phase I Trial Services market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.3. Phase II Trial Services
      • 4.6.3.1. Phase II Trial Services market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.4. Phase III Trial Services
      • 4.6.4.1. Phase III Trial Services market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.5. Phase IV Trial Services
      • 4.6.5.1. Phase IV Trial Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical CRO Market: Molecule Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Pharmaceutical CRO Market Molecule Type Movement Analysis
  • 5.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Molecule Type, 2018 to 2030 (USD Million)
  • 5.4. Small Molecules
    • 5.4.1. Small Molecules market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Large Molecules
    • 5.5.1. Large Molecules market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmaceutical CRO Market: Services Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Pharmaceutical CRO Market Services Movement Analysis
  • 6.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Services, 2018 to 2030 (USD Million)
  • 6.4. Project Management/Clinical Supply Management
    • 6.4.1. Project Management/Clinical Supply Management market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Data Management
    • 6.5.1. Data Management market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Regulatory/Medical Affairs
    • 6.6.1. Regulatory/Medical Affairs market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Medical Writing
    • 6.7.1. Medical Writing market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Clinical Monitoring
    • 6.8.1. Clinical Monitoring market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Quality Management/ Assurance
    • 6.9.1. Quality Management/ Assurance market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. Biostatistics
    • 6.10.1. Bio-statistics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.11. Investigator Payments
    • 6.11.1. Investigator Payments market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.12. Laboratory
    • 6.12.1. Laboratory market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.13. Patient And Site Recruitment
    • 6.13.1. Patient And Site Recruitment market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.14. Technology
    • 6.14.1. Technology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.15. Others
    • 6.15.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Pharmaceutical CRO Market: Therapeutic Areas Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Pharmaceutical CRO Market Therapeutic Areas Movement Analysis
  • 7.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Therapeutic Areas, 2018 to 2030 (USD Million)
  • 7.4. Oncology
    • 7.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. CNS Disorders
    • 7.5.1. CNS Disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Infectious Diseases
    • 7.6.1. Infectious Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Immunological Disorders
    • 7.7.1. Immunological Disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Cardiovascular Disease
    • 7.8.1. Cardiovascular Disease market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. Respiratory Diseases
    • 7.9.1. Respiratory Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.10. Diabetes
    • 7.10.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.11. Ophthalmology
    • 7.11.1. Ophthalmology market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.12. Pain Management
    • 7.12.1. Pain Management market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.13. Other
    • 7.13.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Pharmaceutical CRO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. Regulatory Landscape
      • 8.4.2.4. Reimbursement Scenario
      • 8.4.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Regulatory Landscape
      • 8.4.3.4. Reimbursement Scenario
      • 8.4.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Competitive scenario
      • 8.4.4.3. Regulatory Landscape
      • 8.4.4.4. Reimbursement Scenario
      • 8.4.4.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Regulatory Landscape
      • 8.5.2.4. Reimbursement Scenario
      • 8.5.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. Regulatory Landscape
      • 8.5.3.4. Reimbursement Scenario
      • 8.5.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. Regulatory Landscape
      • 8.5.4.4. Reimbursement Scenario
      • 8.5.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Regulatory Landscape
      • 8.5.5.4. Reimbursement Scenario
      • 8.5.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. Regulatory Landscape
      • 8.5.6.4. Reimbursement Scenario
      • 8.5.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Competitive scenario
      • 8.5.7.3. Regulatory Landscape
      • 8.5.7.4. Reimbursement Scenario
      • 8.5.7.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.8. Norway
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Competitive scenario
      • 8.5.8.3. Regulatory Landscape
      • 8.5.8.4. Reimbursement Scenario
      • 8.5.8.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key country dynamics
      • 8.5.9.2. Competitive scenario
      • 8.5.9.3. Regulatory Landscape
      • 8.5.9.4. Reimbursement Scenario
      • 8.5.9.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Regulatory Landscape
      • 8.6.2.4. Reimbursement Scenario
      • 8.6.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. Regulatory Landscape
      • 8.6.3.4. Reimbursement Scenario
      • 8.6.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Competitive scenario
      • 8.6.4.3. Regulatory Landscape
      • 8.6.4.4. Reimbursement Scenario
      • 8.6.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Competitive scenario
      • 8.6.5.3. Regulatory Landscape
      • 8.6.5.4. Reimbursement Scenario
      • 8.6.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Competitive scenario
      • 8.6.6.3. Regulatory Landscape
      • 8.6.6.4. Reimbursement Scenario
      • 8.6.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Competitive scenario
      • 8.6.7.3. Regulatory Landscape
      • 8.6.7.4. Reimbursement Scenario
      • 8.6.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Regulatory Landscape
      • 8.7.2.4. Reimbursement Scenario
      • 8.7.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Regulatory Landscape
      • 8.7.3.4. Reimbursement Scenario
      • 8.7.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Competitive scenario
      • 8.8.2.3. Regulatory Landscape
      • 8.8.2.4. Reimbursement Scenario
      • 8.8.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Competitive scenario
      • 8.8.3.3. Regulatory Landscape
      • 8.8.3.4. Reimbursement Scenario
      • 8.8.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Competitive scenario
      • 8.8.4.3. Regulatory Landscape
      • 8.8.4.4. Reimbursement Scenario
      • 8.8.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key country dynamics
      • 8.8.5.2. Competitive scenario
      • 8.8.5.3. Regulatory Landscape
      • 8.8.5.4. Reimbursement Scenario
      • 8.8.5.5. Israel market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2023
  • 9.4. Company Profiles/Listing
    • 9.4.1. Parexel International (MA) Corporation.
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. ICON plc
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Laboratory Corporation of America Holdings
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Thermo Fisher Scientific Inc.
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Medpace
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. IQVIA
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. CTI Clinical Trial & Consulting
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. WuXi AppTec
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Veeda Clinical Research
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-470-0

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 5 Global Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 6 Global Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 7 Global Pharmaceutical CRO, by region, 2018 - 2030 (USD Million)
  • Table 8 North America Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 10 North America Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 11 North America Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 12 U.S. Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 15 Canada Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 18 Canada Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 19 Mexico Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 20 Mexico Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 21 Mexico Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 22 Mexico Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 23 Europe Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 24 Europe Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 25 Europe Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 26 Europe Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 27 Germany Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 29 Germany Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 30 Germany Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 31 UK Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 32 UK Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 33 UK Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 34 UK Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 35 France Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 36 France Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 37 France Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 38 France Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 39 Italy Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 40 Italy Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 41 Italy Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 42 Italy Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 43 Spain Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 44 Spain Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 45 Spain Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 46 Spain Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 47 Denmark Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 48 Denmark Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 49 Denmark Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 50 Denmark Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 51 Norway Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 52 Norway Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 53 Norway Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 54 Norway Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 55 Sweden Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 56 Sweden Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 57 Sweden Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 58 Sweden Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Pharmaceutical CRO, by Country, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 64 China Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 65 China Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 66 China Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 67 China Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 68 Japan Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 69 Japan Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 70 Japan Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 71 Japan Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 72 India Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 73 India Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 74 India Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 75 India Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 76 South Korea Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 77 South Korea Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 78 South Korea Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 79 South Korea Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 80 Australia Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 81 Australia Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 82 Australia Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 83 Australia Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 84 Thailand Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 85 Thailand Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 86 Thailand Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 87 Thailand Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 88 Latin America Pharmaceutical CRO, by Country, 2018 - 2030 (USD Million)
  • Table 89 Latin America Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 90 Latin America Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 91 Latin America Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 92 Latin America Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 93 Brazil Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 94 Brazil Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 95 Brazil Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 96 Brazil Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 97 Argentina Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 98 Argentina Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 99 Argentina Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 100 Argentina Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 101 Middle East & Africa Pharmaceutical CRO, by Country, 2018 - 2030 (USD Million)
  • Table 102 Middle East & Africa Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 106 South Africa Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 107 South Africa Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 108 South Africa Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 109 South Africa Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 114 UAE Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 115 UAE Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 116 UAE Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 117 UAE Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Pharmaceutical CRO Market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot 1
  • Fig. 14 Segment snapshot 2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Pharmaceutical CRO Market: Type outlook key takeaways
  • Fig. 20 Pharmaceutical CRO Market: Type movement analysis
  • Fig. 21 Drug Discovery estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Target Validation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Lead Identification market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Lead Optimization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Pre-Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Phase I Trial Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Phase II Trial Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Phase III Trial Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Phase IV Trial Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Pharmaceutical CRO Market: Molecule Type outlook key takeaways
  • Fig. 32 Pharmaceutical CRO Market: Molecule Type movement analysis
  • Fig. 33 Small Molecules market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Large Molecules market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Pharmaceutical CRO Market: Services outlook key takeaways
  • Fig. 36 Pharmaceutical CRO Market: Services movement analysis
  • Fig. 37 Project Management/Clinical Supply Management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Data Management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Regulatory/Medical Affairs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Medical Writing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Clinical Monitoring market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Quality Management/ Assurance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Bio-statistics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Investigator Payments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Laboratory market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Patient And Site Recruitment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Technology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Pharmaceutical CRO Market: Therapeutic Areas outlook key takeaways
  • Fig. 50 Pharmaceutical CRO Market: Therapeutic Areas movement analysis
  • Fig. 51 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 CNS Disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Infectious Diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Immunological Disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Cardiovascular Disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Respiratory Diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Ophthalmology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Pain Management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Regional marketplace outlook, 2023 & 2030 (USD Million)
  • Fig. 62 Regional marketplace: Key takeaways
  • Fig. 63 North America Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 U.S. Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Canada Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Mexico Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Europe Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 UK Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Germany Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 France Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Spain Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Italy Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Denmark Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Norway Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Sweden Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Asia Pacific Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Japan Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 China Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 India Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Australia Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 South Korea Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Thailand Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Latin America Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Brazil Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 Argentina Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 MEA Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 South Africa Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 Saudi Arabia Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Key country dynamics
  • Fig. 112 UAE Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 Kuwait Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Market participant categorization
  • Fig. 116 Pharmaceutical CRO Market position analysis, 2023
  • Fig. 117 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!